{
  "item1": "BUSINESS Amgen Inc. (including its subsidiaries, referred “Amgen,” “the Company,” “we,” “our” “us”) discovers, develops, manufactures delivers innovative medicines fight some world’s toughest diseases. focus areas high unmet medical need leverage expertise strive solutions dramatically improve people’s lives, while also reducing social economic burden disease. helped launch biotechnology industry more than 40 years ago grown one world’s leading independent biotechnology companies.",
  "item7": "— U.S. Total other product sales Total U.S. — other products Total ROW — other products Total other product sales N/A = not applicable * Change excess 100% RAVICTI, UPLIZNA PROCYSBI acquired Horizon acquisition October 6, 2023, include product sales periods after acquisition date. Consists product sales (i) KANJINTI, RIABNI, AVSOLA, NEUPOGEN, Corlanor, IMLYGIC, BEKEMV, PAVBLU, WEZLANA/WEZENLA Sensipar/Mimpara; (ii) ACTIMMUNE, RAYOS, BUPHENYL, QUINSAIR, PENNSAID DUEXIS periods after Horizon acquisition October 6, 2023.",
  "item2": "Interest expense, net Provision income taxes Interest expense, net Interest expense, net, decreased three nine months ended September 30, 2025, primarily due lower average debt outstanding. Other income, net, increased three nine months ended September 30, 2025, primarily due higher net unrealized gains equity investments, primarily BeOne. See Note 6, Investments, condensed consolidated financial statements. increase effective tax rate three months ended September 30, 2025, primarily due change earnings mix, including lower amortization expense fair value step-up inventory acquired Horizon."
}